A panel of markers for identification of malignant and non-malignant cells in culture from effusions.

The aim of the present study was to identify cell types in primary culture from malignant and non-malignant effusions. Effusion samples were subjected to cytology and culture. Immunocytochemistry was performed in cytological slides to evaluate malignancy (positivity for malignancy markers) and in culture slides for identification of cell types in growth. A total of 143 effusion samples (pleural n=76; peritoneal n=37; pericardial n=4; and peritoneal lavage n=26) were analyzed. Cell growth was observed in 34.9% of all samples and immunocytochemistry for identification of cell types in culture slides was conclusive in 90% of them. In non-malignant samples (n=28), growth of mesothelial cells, macrophages and of both cell types was identified in 82.14, 10.71 and 7.14%, respectively. In malignant samples (n=17, all carcinomas), growth of malignant epithelial cells and of both malignant epithelial and mesothelial cells was identified in 41.17 and 23.52%, respectively. In the remaining 35.29% of malignant samples, the only cells in growth were mesothelial and/or macrophages instead of malignant epithelial cells. In conclusion, in culture of malignant effusions, mesothelial cells may be simultaneously identified with malignant epithelial cells. Besides, mesothelial cells and macrophages may be the only cells identified in malignant effusion culture. Therefore, a broad panel of cell markers should be used for unmistakable identification of cells in studies of effusion primary culture. The ideal malignant effusion sample to obtain culture of neoplastic cells should be that without the presence of mesothelial cells and macrophages.

[1]  C. Kong,et al.  Immunohistochemistry for the detection of renal cell carcinoma in effusion cytology , 2011, Diagnostic cytopathology.

[2]  M. Roh,et al.  Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions , 2015, Cancer cytopathology.

[3]  B. Shuch,et al.  PAX-8 expression in renal tumours and distant sites: A useful marker of primary and metastatic renal cell carcinoma? , 2014, Journal of Clinical Pathology.

[4]  L. Bubendorf,et al.  Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine , 2016, PloS one.

[5]  J. M. Porcel,et al.  TTF‐1 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions , 2015, Respirology.

[6]  T. Chan,et al.  Peritoneal Mesothelial Cell Culture and Biology , 2006, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[7]  S. Yung,et al.  Mesothelial Cells , 2007, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[8]  G. Kaygusuz,et al.  The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma. , 2010, Pathology, research and practice.

[9]  J. Lee,et al.  Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks , 2009, Diagnostic cytopathology.

[10]  Y. Hosomi,et al.  Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis , 2015, Thoracic cancer.

[11]  J. Lee,et al.  Diagnostic Usefulness of Claudin-3 and Claudin-4 for Immunocytochemical Differentiation between Metastatic Adenocarcinoma Cells and Reactive Mesothelial Cells in Effusion Cell Blocks , 2016, Acta Cytologica.

[12]  W. Han,et al.  Establishment and characterization of seven human breast cancer cell lines including two triple-negative cell lines. , 2013, International journal of oncology.

[13]  K. Kapila,et al.  Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma—a pilot study , 2016, Diagnostic cytopathology.

[14]  B. Delahunt,et al.  Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non‐prostatic origin: a comparative study , 2016, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[15]  Ryan McKnight,et al.  Utility of paired box gene 8 (PAX8) expression in fluid and fine‐needle aspiration cytology , 2010, Cancer cytopathology.

[16]  J. Kinoshita,et al.  The role of human peritoneal mesothelial cells in the fibrosis and progression of gastric cancer , 2012, International journal of oncology.

[17]  S. Haan,et al.  What Do We Learn from Spheroid Culture Systems? Insights from Tumorspheres Derived from Primary Colon Cancer Tissue , 2016, PloS one.

[18]  A. Marchevsky,et al.  Evidence‐based guidelines to optimize the selection of antibody panels in cytopathology: Pleural effusions with malignant epithelioid cells , 2009, Diagnostic cytopathology.

[19]  M. Takano,et al.  Immunocytochemical utility of claudin‐4 versus those of Ber‐EP4 and MOC‐31 in effusion cytology , 2016, Diagnostic cytopathology.

[20]  S. Masood,et al.  Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: The utility of immunocytochemical panel in the differential diagnosis , 2009, Diagnostic cytopathology.

[21]  L. Fattore,et al.  TrkB is responsible for EMT transition in malignant pleural effusions derived cultures from adenocarcinoma of the lung , 2013, Cell cycle.

[22]  B. Xie,et al.  Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry , 2011, Diagnostic cytopathology.

[23]  N. Sneige,et al.  Value of PAX8 and WT1 Immunostaining in Confirming the Ovarian Origin of Metastatic Carcinoma in Serous Effusion Specimens. , 2012, American journal of clinical pathology.

[24]  L Antonangelo,et al.  Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results. , 2015, Current oncology.

[25]  A. Simsir,et al.  Comparison of antibodies to HBME‐1 and calretinin for the detection of mesothelial cells in effusion cytology , 2001, Diagnostic cytopathology.

[26]  D. Coffey,et al.  Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology? , 2009, Archives of pathology & laboratory medicine.

[27]  Yuquan Wei,et al.  Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway* , 2016, The Journal of Biological Chemistry.

[28]  Q. K. Li,et al.  Morphologic and immunocytochemical performances of effusion cell blocks prepared using 3 different methods. , 2013, American journal of clinical pathology.

[29]  R. Mancini,et al.  Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity , 2016, Journal of Translational Medicine.

[30]  P. Bourne,et al.  Utility of anti‐L523S antibody in the diagnosis of benign and malignant serous effusions , 2007, Cancer.

[31]  E. Srivatsan,et al.  The Malignant Pleural Effusion as a Model to Investigate Intratumoral Heterogeneity in Lung Cancer , 2009, PloS one.

[32]  S. Mutsaers,et al.  Stimulation of mesothelial cell proliferation by exudate macrophages enhances serosal wound healing in a murine model. , 2002, The American journal of pathology.

[33]  N. Cha,et al.  Expression and significance of MOC‐31 and calretinin in pleural fluid of patients with lung cancer , 2015, Diagnostic cytopathology.

[34]  Y. Kudryavets,et al.  Establishment and characterization of new breast and ovarian cancer cell lines as a model for studying cellular plasticity in vitro. , 2016, Experimental oncology.

[35]  L. Truong,et al.  PAX2 and PAX8: Useful Markers for Metastatic Effusions , 2013, Acta Cytologica.

[36]  Yaoh-Shiang Lin,et al.  Pulmonary Adenocarcinoma in Malignant Pleural Effusion Enriches Cancer Stem Cell Properties during Metastatic Cascade , 2013, PloS one.

[37]  Xueqing Yu,et al.  Isolation and Propagation of Rat Peritoneal Mesothelial Cells. , 2016, Methods in molecular biology.

[38]  S. Krishnamurthy,et al.  Use of the monoclonal antibody MOC‐31 as an immunomarker for detecting metastatic adenocarcinoma in effusion cytology , 2011, Cancer cytopathology.

[39]  M. Torrisi,et al.  High Adhesion of Tumor Cells to Mesothelial Monolayers Derived from Peritoneal Wash of Disseminated Gastrointestinal Cancers , 2013, PloS one.

[40]  M. Tzardi,et al.  Cytology of Pericardial Effusion due to Malignancy , 2016, Romanian journal of internal medicine = Revue roumaine de medecine interne.

[41]  P. Ziprin,et al.  Investigation of tumor-peritoneal interactions in the pathogenesis of peritoneal metastases using a novel ex vivo peritoneal model. , 2010, The Journal of surgical research.

[42]  Grace E. Kim,et al.  SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type , 2016, The American journal of surgical pathology.

[43]  Z. Tabatabai,et al.  The Diagnostic Utility of D2-40, Calretinin, CK5/6, Desmin and MOC-31 in the Differentiation of Mesothelioma from Adenocarcinoma in Pleural Effusion Cytology , 2012, Acta Cytologica.

[44]  G. Lazopoulos,et al.  Pleural effusion cytology due to malignancy. A combined cytomorphological-immunocytochemical study of 500 cases. , 2016, Revista portuguesa de pneumologia.